Regístrese
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Tratamiento con daptomicina en pacientes diabéticos
Información de la revista
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 54-58 (Febrero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 54-58 (Febrero 2012)
DOI: 10.1016/S0213-005X(12)70073-3
Acceso a texto completo
Tratamiento con daptomicina en pacientes diabéticos
Daptomycin in diabetic patients
Visitas
2082
Miguel Montejo
Unidad de Enfermedades Infecciosas, Hospital Universitario de Cruces, Barakaldo, España
Este artículo ha recibido
2082
Visitas
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

En los pacientes diabéticos la prevalencia de portador de Staphylococcus aureus en piel o nasal es alta, lo que se asocia con un incremento del riesgo para presentar infecciones locales o sistémicas y, por tanto, un aumento de la morbimortalidad. Los microorganismos responsables en la mayoría de las infecciones en las úlceras y pie diabético son S. aureus y Streptococcus pyogenes, aunque las infecciones crónicas del pie diabético generalmente son polimicrobianas, incluyendo Pseudomonas aeruginosa y enterobacterias. En este trabajo se recoge la experiencia con daptomicina en el tratamiento de las complicaciones infecciosas más frecuentes que presentan los pacientes diabéticos. En el registro CORE (Cubicin Outcomes Registry and Experience) se observaron 60 pacientes con infección de piel y tejidos blandos tratados con daptomicina, obteniéndose éxito terapéutico en el 83% de los casos. Otros estudios recientes que comparan daptomicina con vancomicina o penicilinas semisintéticas han demostrado también la eficacia y seguridad de daptomicina, con tasas de curación de entre el 70–80% de los casos. En el registro europeo (EUCORE), en los pacientes diabéticos que desarrollaron bacteriemia o endocarditis por grampositivos y que habían recibido daptomicina, se obtuvo éxito en el 76,8 y el 72%, respectivamente. En un estudio que comparaba daptomicina o terapia estándar con vancomicina en infección por S. aureus resistente a la meticilina o penicilina antiestafilocócica en infecciones por S. aureus sensible a la meticilina en diabéticos con bacteriemia o endocarditis, no se encontraron diferencias significativas. La rápida acción bactericida y escasos efectos secundarios hacen que daptomicina sea un antimicrobiano atractivo en el tratamiento de infecciones por grampositivos que presentan los pacientes diabéticos, bien en monoterapia o en asociación con otros fármacos.

Palabras clave:
Daptomicina
Grampositivos
Diabetes
Piel y tejidos blandos
Bacteriemia
Endocarditis
Biopelículas
Abstract

In diabetic patients, there is a high prevalence of skin or nasal carriage of Staphylococcus aureus, which is associated with an increased risk of local or systemic infections and consequently with greater morbidity and mortality. The microorganisms causing most infections in diabetic ulcers and diabetic foot are S. aureus and Streptococcus pyogenes, although chronic diabetic foot infections are generally polymicrobial, including Pseudomonas aeruginosa and enterobacteria. The present article describes experience with daptomycin in the treatment of the most frequent infectious complications in diabetic patients. The Cubicin Outcomes Registry and Experience (CORE) registry contains information on 60 patients with skin and soft tissue infections treated with daptomycin, with a success rate of 83%. Other recent studies comparing daptomycin with vancomycin or semi-synthetic penicillins have also shown the efficacy and safety of daptomycin with cure rates of between 70% and 80%. In the European version of the CORE registry, the EUROCORE, diabetic patients who developed bacteremia or endocarditis due to Gram-positive pathogens and who received daptomycin showed success rates of 76.8% and 72%, respectively. No significant differences were found in a study comparing daptomycin or standard therapy with vancomycin in methicillin-resistant S. aureus (MRSA) or antistaphylococcal penicillin in methicillin-susceptible S. aureus (MSSA) in diabetic patients with bacteremia or endocarditis. Because of its rapid bactericidal action and scarce adverse effects, daptomycin is an attractive antimicrobial agent in the treatment of Gram-positive infections in diabetic patients, whether in monotherapy or in association with other agents.

Keywords:
Daptomycin
Gram-positive
Diabetes
Skin and soft tissues
Bacteremia
Endocarditis
Biofilms
El Texto completo solo está disponible en PDF
Bibliografía
[1.]
G. Van den Berghe, P. Wouters, F. Weekers, C. Verwaest, F. Bruyninckx, M. Schetz, et al.
Intensive insulin therapy in the critically ill patients.
N Engl J Med, 345 (2001), pp. 1359-1367
[2.]
N. Borregaard, T. Herlin.
Energy metabolism of human neutrophils during phagocytosis.
J Clin Invest, 70 (1982), pp. 550-557
[3.]
S.H. Kim, K.W. Park, Y.S. Kim, S. Oh, I.H. Chae, H.S. Kim, et al.
Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism.
Endothelium, 10 (2003), pp. 65-70
[4.]
F. Santilli, F. Cipollone, A. Mezzetti, F. Chiarelli.
The role of nitric oxide in the development of diabetic angiopathy.
Horm Metab Res, 36 (2004), pp. 319-335
[5.]
M.J. Sampson, I.R. Davies, J.C. Brown, K. Ivory, D.A. Hughes.
Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients.
Arterioscler Thromb Vasc Biol, 22 (2002), pp. 1187-1193
[6.]
L. Bergamaschini, M. Gardinali, M. Poli, R. Lorini, E. Bosi, A. Agostoni.
Complement activation in diabetes mellitus.
J Clin Lab Immunol, 35 (1991), pp. 121-127
[7.]
D. Saiepour, J. Sehlin, P.A. Oldenborg.
Hyperglycemia-induced protein kinase C activation inhibits phagocytosis of C3b- and immunoglobulin gopsonized yeast particles in normal human neutrophils.
Exp Diabesity Res, 4 (2003), pp. 125-132
[8.]
M. Turina, D.E. Fry, H.C. Polk Jr..
Acute hyperglycemia and the innate immune system: clinical, cellular, and molecular aspects.
Crit Care Med, 33 (2005), pp. 1624-1633
[9.]
W. Marhoffer, M. Stein, E. Maeser, K. Federlin.
Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes.
Diabetes Care, 15 (1992), pp. 256-260
[10.]
A.Y. Peleg, T. Weerarathna, J.S. McCarthy, T.M. Davis.
Common infections in diabetes: pathogenesis, management and relationship to glycaemic control.
Diabetes Metab Res Rev, 23 (2007), pp. 3-13
[11.]
L.M. Muller, K.J. Gorter, E. Hak, W.L. Goudzwaard, F.G. Schellevis, A.I. Hoepelman, et al.
Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.
Clin Infect Dis, 41 (2005), pp. 281-288
[12.]
M. Gabillot-Carre, J.C. Roujeau.
Acute bacterial skin infections and cellulitis.
Curr Opin Infect Dis, 20 (2007), pp. 118-123
[13.]
D.V. Seal.
Necrotizing fasciitis.
Curr Opin Infect Dis, 14 (2001), pp. 127-132
[14.]
B.A. Lypsky, A.R. Berendt, H.G. Deery, J.M. Embil, W.S. Joseph, A.W. Karchmer.
Diagnosis and treatment of diabetic foot infections.
Clin Infect Dis, 39 (2004), pp. 885-910
[15.]
F. Traunmüller, M.V. Schintler, J. Metzler, S. Spendel, O. Mauric, M. Popovic, et al.
Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.
J Antimicrob Chemother, 65 (2010), pp. 1252-1257
[16.]
A. Imaz, M. Pujol, P. Barragán, M.A. Domínguez, J.M. Tiraboschi, D. Podzamczer.
Community associated methicillin-resistant Staphylococcus aureus in HIV infected patients.
AIDS Rev, 12 (2010), pp. 153-163
[17.]
J. Rodríguez-Baño, M.A. Domínguez, A. Blas Millán, C. Borraz, M. Pau González, B. Almirante, et al.
Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain.
Clin Microbiol Infect, 15 (2009), pp. 1111-1118
[18.]
P.I. Hair, S.J. Keam.
Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.
Drugs, 67 (2007), pp. 1483-1512
[19.]
R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, B.I. Eisenstein.
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.
Clin Infect Dis, 38 (2004), pp. 1673-1681
[20.]
S.L. Davis, P.S. McKinnon, L.M. Hall, G. Delgado Jr., W. Rose, R.F. Wilson, et al.
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Pharmacotherapy, 27 (2007), pp. 1611-1618
[21.]
I.A. Bliziotis, E. Plessa, G. Peppas, M.E. Falagas.
Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a metaanalysis.
Ann Pharmacother, 44 (2010), pp. 97-106
[22.]
R.C. Owens Jr., K.C. Lamp, L.V. Friedrich, R. Russo.
Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Am J Med, 120 (2007), pp. S6-S12
[23.]
A. Sotto, D. Laouini, N. Bouziges, N. Jourdan, J.L. Richard, J.P. Lavigne.
In vitro activity of daptomycin against strains isolated from diabetic foot ulcers.
Pathol Biol (Paris), 58 (2010), pp. 73-77
[24.]
C.B. Landersdorfer, J.B. Bulitta, M. Kinzig, U. Holzgrabe, F. Sörgel.
Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.
Clin Pharmacokinet, 48 (2009), pp. 89-124
[25.]
K. Johnson, K.C. Lamp, L.V. Friedrich.
Retrospective review of the use of daptomycin for diabetic foot infections.
J Wound Care, 18 (2009), pp. 396-400
[26.]
W.V. Kern.
Daptomycin: first in a new class of antibiotic for complicated skin and soft-tissue infections.
Int J Clin Prat, 60 (2006), pp. 370-378
[27.]
B.A. Lipsky, U. Stoutenburgh.
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
J Antimicrob Chemother, 55 (2005), pp. 240-245
[28.]
M. Cruciani, B.A. Lipsky, C. Mengoli, F. De Lalla.
Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis.
Diabetes Care, 28 (2005), pp. 454-460
[29.]
C. Fossaceca.
Outcomes analysis of daptomycin use in a community hospital.
Adv Ther, 24 (2007), pp. 517-528
[30.]
S.L. Davis, P.S. McKinnon, L.M. Hall, G. Delgado Jr., W. Rose, R.F. Wilson, et al.
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
Pharmacotherapy, (2007), pp. 1611-1618
[31.]
C. Senior.
Treatment of diabetes foot ulcers with hyperbaric oxygen.
J Wound Care, 94 (2000), pp. 193-197
[32.]
P.V. Sreeramoju, J. Tolentino, S. García-Houchins, S.G. Weber.
Predictive factors for the development of central line-associated bloodstream infection due to gramnegative bacteria in intensive care unit patients after surgery.
Infect Control Hosp Epidemiol, 29 (2008), pp. 51-56
[33.]
K. Kreisel, K. Boyd, P. Langenberg, M.C. Roghmann.
Risk factors for recurrence in patients with Staphylococcus aureus infections complicated by bacteremia.
Diagn Microbiol Infect Dis, 55 (2006), pp. 179-184
[34.]
R. Moreno, J. Zamorano, C. Almería, A. Villate, J.L. Rodrigo, D. Herrera, et al.
Influence of diabetes mellitus on short- and long-term outcome in patients with active infective endocarditis.
J Heart Valve Dis, 11 (2002), pp. 651-659
[35.]
C.H. Cabell, J.G. Jollis, G.E. Peterson, G.R. Corey, D.J. Anderson, D.J. Sexton, et al.
Changing patient characteristics and the effect on mortality in endocarditis.
Arch Intern Med, 162 (2002), pp. 90-94
[36.]
J. Bishara, N. Peled, Z. Samra, A. Sagie, L. Leibovici, S. Pitlik.
Infective endocarditis in diabetic and non-diabetic patients.
Scand J Infect Dis, 36 (2004), pp. 795-798
[37.]
J. Garnacho Montero, R. Amaya Villar, M.L. Gómez Grande, V. Jerez Gómez-Coronado, L. Lorente Ramos, A. Loza Vázquez, et al.
Papel de daptomicina en el tratamiento empirico y dirigido de infecciones por cocos grampositivos del paciente crítico.
Rev Esp Quimioter, 24 (2011), pp. 13-24
[38.]
Z.A. Kanafani, W.M. Kourany, V.G. Fowler Jr., D.P. Levine, G.A. Vigliani, M. Campion, et al.
Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.
Eur J Clin Microbiol Infect Dis, 28 (2009), pp. 1477-1482
[39.]
De Alarcón A, Fariñas C, Muñoz P, Montejo-Baranda JM, Miró JM, Fernández-Hidalgo N, et al. Use of daptomycin in infective endocarditis. Results of a multicentric cohort. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Chicago, September 17-20-2011. Abstract K-1904.
[40.]
J. Mensa, J. Barberan, P. Lliñares, J. Picazo, E. Bouza, F. Álvarez-Lerma, et al.
Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina.
Rev Esp Quimioter, 21 (2008), pp. 67-92
[41.]
F. Gudiol, J.M. Aguado, A. Pascual, M. Pujol, B. Almirante, J.M. Miró, et al.
Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina.
Enferm Infecc Microbiol Clin, 27 (2009), pp. 105-115
[42.]
C.E. Edmiston Jr., M.P. Goheen, G.R. Seabrook, C.P. Johnson, B.D. Lewis, K.R. Brown, et al.
Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices.
Am J Surg, 192 (2006), pp. 344-354
[43.]
I. Raad, H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, G. Chaiban, et al.
Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm.
Antimicrob Agents Chemother, 51 (2007), pp. 1656-1660
[44.]
H.S. Sader, T.R. Fritsche, R.N. Jones.
Antimicrobial activity of daptomycin and selected comparators tested againts bloodstream Staphylococcus aureus isolates from haemodialysis patients.
Int J Infect Dis, 13 (2009), pp. 291-295
[45.]
N.N. Salama, J.H. Segal, M.D. Churchwell, J.H. Patel, L. Gao, M. Heung, et al.
Single dose daptomycin pharmacokinetics in chronic haemodialysis patients.
Nephrol Dial Transplant, 25 (2010), pp. 1279-1284
Copyright © 2012. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.